Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 18/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.46 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.46 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18079925 | 0.91 | P2RY2 (0.53) | P2RY2P2RX3P2RY4P2RY6 | |
| SCHEMBL18079987 | 0.90 | P2RY2 (0.47) | P2RY2P2RX3P2RY4P2RY6 | |
| SCHEMBL18079957 | 0.88 | P2RX3 (0.47) | P2RY2P2RX3P2RY4P2RY6 | |
| SCHEMBL18080006 | 0.88 | P2RY2 (0.45) | P2RY2P2RX3P2RY4P2RY6 | |
| SCHEMBL18080012 | 0.87 | P2RY2 (0.44) | P2RY2P2RX3P2RY4P2RY6 | |
| SCHEMBL18079993 | 0.84 | P2RY2 (0.46) | P2RY2P2RX3P2RY4P2RY6 | |
| SCHEMBL18079988 | 0.83 | P2RX3 (0.46) | P2RY2P2RX3P2RY4RNASELP2RY6 | |
| SCHEMBL18079983 | 0.83 | P2RY2 (0.49) | P2RY2P2RY4P2RY6 | |
| SCHEMBL18079995 | 0.83 | P2RY2 (0.47) | P2RY2P2RX3P2RY4P2RY6 | |
| SCHEMBL18080003 | 0.81 | P2RY2 (0.51) | P2RY2P2RX3P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | POLRMT, POLN, NSUN3 | P2RY2 980/4885P2RX3 846/4885P2RY4 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.